GlassScriptPhysician profile
Sasha M Chediak
NPI 1497142517
$11,237.17
in general payments reported to CMS, 2019-2025
31 companies · $2,570 in 2025
The $2,570 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $453 · 2021: $1,114 · 2022: $1,131 · 2023: $2,341 · 2024: $2,571 · 2025: $2,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,920 · Education: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,919.72 |
| Education | $561.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,838.65 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,558.55 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $725.60 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $687.88 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $642.89 | 2019-2025 | |
| Galderma Laboratories, L.P. | $638.31 | 2019-2025 | Dysport, Nemluvio |
| Regeneron Healthcare Solutions, INC. | $589.55 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $545.84 | 2019-2025 | |
| Incyte Corporation | $502.12 | 2021-2025 | Opzelura |
| Ucb, INC. | $500.98 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $428.91 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $371.73 | 2020-2025 | Winlevi, Ilumya, Absorica Ld |
| Merz North America, INC. | $322.25 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $253.83 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $212.52 | 2022-2023 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $212.29 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $206.16 | 2023-2025 | Jublia, Cabtreo, Arazlo |
| Leo Pharma INC. | $193.49 | 2021-2025 | Adbry |
| Amgen INC. | $172.78 | 2021-2024 | Otezla |
| Organon LLC | $128.65 | 2025 | Vtama |
| Biofrontera INC. | $116.41 | 2019-2025 | Bf-Rhodoled, Ameluz |
| Almirall LLC | $111.87 | 2019-2025 | Klisyri |
| Verrica Pharmaceuticals INC. | $55.91 | 2023-2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.00 | 2022-2023 | Spevigo |
| Pierre Fabre Pharmaceuticals, INC. | $40.78 | 2019 | |
| Mayne Pharma Commercial LLC | $39.45 | 2019 | |
| Blueprint Medicines Corporation | $21.02 | 2023 | |
| Nabriva Therapeutics, Plc | $21.00 | 2022 | |
| Dusa Pharmaceuticals, INC. | $17.34 | 2019 | |
| Tactile Systems Technology INC | $13.80 | 2021 | |
| Epi Health, LLC | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasha Chediak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.